rna
interfer
rnai
evolut
conserv
gene
silenc
mechan
present
varieti
eukaryot
speci
rnai
use
short
doublestrand
rna
dsrna
trigger
degrad
translat
repress
homolog
rna
target
sequencespecif
manner
system
induc
effect
vitro
vivo
direct
applic
small
interf
rna
sirna
express
short
hairpin
rna
shrna
nonvir
viral
vector
date
rnai
extens
use
novel
effect
tool
function
genom
studi
display
great
potenti
treat
human
diseas
includ
human
genet
acquir
disord
cancer
viral
infect
present
review
focu
recent
develop
use
rnai
prevent
treatment
viral
infect
mechan
strategi
hurdl
prospect
employ
rnai
pharmaceut
industri
also
discuss
rna
interfer
rnai
highli
conser
ved
gene
silenc
mechan
play
import
role
regul
gene
express
system
examin
broad
varieti
speci
includ
plant
fungi
yeast
nematod
fli
mammal
fact
rnai
serv
safeguard
preserv
genom
integr
protect
host
viral
infect
invas
mobil
genet
element
degrad
exogen
genom
materi
eg
viral
rna
rnai
trigger
small
doublestrand
rna
r
n
n
f
u
n
c
n
l
l
l
e
l
n
c
l
u
n
g
transcript
posttranscript
translat
first
report
rnainduc
posttranscript
gene
silenc
ptg
phenomena
publish
earli
napoli
van
der
krol
describ
cosuppress
viral
transgen
homolog
endogen
gene
transgen
plant
similar
inactiv
gene
express
call
quell
observ
neurospora
crassa
transform
homolog
sequenc
sens
rna
demonstr
effect
antisens
rna
disrupt
express
caenorhabd
elegan
mechan
action
remain
enigmat
fire
mello
discov
dsrna
instead
singlestrand
sens
antisens
rna
mediat
gene
silenc
degrad
endogen
mrna
sequencespecif
manner
also
challeng
previou
report
publish
claim
artifici
effect
dsrna
contamin
studi
reveal
rnai
occur
transcript
posttranscript
level
transcript
gene
silenc
involv
histon
methyl
format
heterochromatin
posttranscript
gene
silenc
includ
small
interf
rna
sirna
mediat
sequencespecif
target
rna
degrad
micro
rna
mirna
promot
blockag
protein
translat
region
recent
year
rnai
becom
power
tool
probe
gene
function
ration
drug
design
employ
prophylact
therapeut
agent
combat
wide
rang
disord
includ
infecti
diseas
tumor
metabol
disord
sever
lethal
virus
includ
human
immunodefici
viru
hiv
hepat
c
b
virus
hcv
hbv
coronaviru
influenza
viru
iav
human
papillomaviru
hpv
shown
inhibit
elimin
rnai
find
emphas
potenti
rnai
clinic
applic
present
review
discuss
mechan
rnai
role
prevent
treatment
viral
infect
sever
compon
risc
identifi
includ
conserv
argonaut
protein
share
paz
domain
dicer
famili
protein
dicer
also
cleav
long
precursor
mirna
premirna
mirna
similar
size
sirna
pathway
refer
mirnadepend
gene
silenc
premirna
whose
structur
imperfectli
complementari
strand
gener
endogen
stem
loop
precursor
hairpin
name
primarymirna
primirna
primirna
first
cleav
drosha
rnase
nucleu
result
premirna
export
cytoplasm
process
dicer
complex
activ
risc
mirna
bind
specif
mrna
trigger
cleavag
perfect
basepair
translat
repress
partial
basepair
recognit
order
studi
function
genom
biolog
rna
interfer
much
effort
gone
studi
digest
long
dsrna
sirna
transient
transfect
target
cell
altern
short
hairpin
rna
shrna
express
endogen
plasmid
viral
vector
shrna
express
cassett
stabli
integr
genom
target
cell
transcrib
intranuclearli
process
sirna
dicer
cytosol
gener
rna
pol
promot
ie
trna
promot
commonli
use
drive
shrna
express
rnai
studi
viral
vector
includ
retro
lenti
adenoand
adenoassoci
viral
vector
demonstr
featur
higheffici
gene
deliveri
overcom
obstacl
celltypedepend
transfect
develop
induc
rnai
system
certainli
enhanc
understand
candid
gene
function
provid
invalu
genet
switcher
allow
induc
revers
control
specif
gene
express
vitro
vivo
viral
infect
seriou
public
health
social
econom
problem
effect
approach
urgent
need
prevent
viral
propag
sever
studi
shown
rnai
technolog
potenti
advantag
tradit
measur
use
antivir
drug
vaccin
eas
use
rapid
action
high
effici
specif
activ
appli
differ
stage
virushost
interact
section
focu
prospect
use
rnai
sever
common
human
pathogen
hiv
hcv
hbv
sarscoronaviru
influenza
viru
human
immunodefici
viru
type
first
primat
viru
shown
inhibit
rnai
hiv
retroviru
categor
subgroup
lentivirus
upon
infect
posit
strand
hiv
rna
genom
revers
transcript
linear
dsdna
soon
viru
enter
host
cell
receptor
recognit
cell
adhes
linear
dsdna
becom
circular
transport
nucleu
integr
host
chromosom
proviru
util
host
enzym
hiv
proviru
convert
viral
gene
mrna
use
blueprint
subsequ
express
viral
structur
protein
enzym
suggest
genom
rna
newli
transcrib
viral
mrna
good
target
sirna
intervent
unclear
whether
rnai
target
rna
genom
infecti
particl
jacqu
report
sirnamedi
inhibit
earli
late
step
replic
target
variou
region
genom
prevent
mation
viral
complementarydna
intermedi
worker
suggest
incom
rna
genom
may
access
sirna
date
sever
viral
target
sequenc
identifi
includ
structur
protein
gag
env
revers
transcriptas
pol
regulatori
protein
tat
rev
two
accessori
protein
nef
vif
tabl
long
termin
repeat
integras
employ
insert
hiv
dna
genom
host
dna
also
target
sever
studi
demonstr
hiv
may
abl
escap
rnai
target
mutat
overcom
problem
lentivir
vector
incorpor
differ
shrnaexpressingcassett
simultan
target
multipl
sequenc
includ
conserv
sequenc
hiv
genom
construct
anoth
propos
strategi
use
rnai
applic
target
host
gene
host
gene
essenti
viral
replic
much
slower
mutat
rate
viral
gene
gene
target
rnai
result
encourag
tabl
downregul
cell
surfac
receptor
andor
one
coreceptor
rnai
led
dramat
reduct
viral
entri
cell
compar
found
preferenti
target
sinc
immun
defect
host
mortal
observ
delet
therefor
care
select
host
immut
cofactor
import
viral
replic
host
surviv
prime
import
develop
antihiv
strategi
furthermor
simultan
target
rnai
viru
host
factor
shown
effect
inhibit
replic
target
either
viru
host
factor
alon
hepat
c
viru
infect
major
caus
chronic
liver
diseas
includ
liver
cirrhosi
hepatocellular
carcinoma
hcc
estim
number
infect
individu
million
worldwid
account
nearli
world
popul
world
health
organ
recogn
hcv
infect
global
health
problem
hcv
small
envelop
rna
viru
belong
flavivirida
famili
cytoplasm
replic
viru
contain
kb
rna
genom
function
messeng
rna
replic
templat
develop
antihcv
drug
acceler
sinc
repliconbas
cultur
system
establish
year
ago
sever
region
hcv
rna
genom
includ
code
sequenc
core
sensit
action
sirna
tabl
therapeut
potenti
rnai
emphas
vivo
studi
administr
sirna
shrna
target
cell
surfac
receptor
fa
caspas
result
destruct
cognat
mrna
protect
mice
liver
failur
use
multipl
sirna
highli
conserv
hcv
sequenc
without
host
cell
cofactor
may
limit
emerg
resist
virus
demonstr
sever
studi
tabl
wwwwjgnetcom
hepat
b
viru
infect
major
public
health
problem
estim
approxim
billion
peopl
infect
hbv
worldwid
million
hbv
chronic
carrier
hbv
infect
highli
preval
asia
south
africa
result
one
million
death
worldwid
annual
although
clinic
symptom
caus
hbv
hcv
infect
similar
virus
complet
unrel
hbv
prototyp
member
hepadnavirida
famili
one
smallest
dna
virus
kb
undergo
reversetranscript
viral
replic
hbv
genom
contain
four
overlap
open
read
frame
p
polymeraserevers
transcriptas
c
core
structur
protein
surfac
glycoprotein
x
hbx
protein
uncoat
nucleocapsid
enter
nucleu
hbv
genom
repair
form
coval
close
circular
dna
cccdna
templat
messeng
rna
transcript
rna
intermediatespregenom
subgenom
rna
code
viral
multifunct
protein
transport
cytoplasm
translat
initi
pregenom
transcript
packag
virion
core
particl
revers
transcrib
viral
revers
transcriptas
thu
produc
singl
strand
dna
base
structur
strand
dna
complementari
dna
strand
synthes
due
lack
proofread
function
polymeras
hbv
undergo
rapid
mutagenesi
creation
larg
number
drugresist
variant
drugresist
variant
amplifi
select
pressur
antivir
treatment
result
elimin
antivir
effect
viru
rebound
treatment
sever
case
lead
death
even
cessat
treatment
challeng
new
drug
differ
target
drug
metabol
mechan
urgent
requir
better
treatment
outcom
sever
site
hbv
genom
includ
p
pre
fold
inhibit
viru
product
refer
result
obtain
potent
sirnashrna
test
specif
cell
model
cc
press
x
gene
employ
target
examin
vitro
efficaci
rnai
tabl
site
also
test
hydrodynam
hbv
model
transgen
hbv
model
tabl
group
success
design
multipl
shrna
target
dr
element
region
code
core
polymeras
pre
x
protein
shrna
found
potent
inhibit
hbv
replic
show
synergist
antivir
effect
commonli
use
antivir
drug
lamivudin
recent
studi
show
simultan
deliveri
two
shrna
target
differ
region
exhibit
strong
synergist
antivir
effect
hydrodynam
transgen
mice
model
studi
e
antigen
reduc
undetect
level
viral
load
reduc
greater
one
hundredfold
et
al
unpublish
observ
result
clearli
demonstr
potenti
rnai
applic
antihbv
therapi
sever
acut
respiratori
syndrom
sar
outbreak
affect
nearli
countri
year
epidem
caus
novel
sarsassoci
coronaviru
sarscov
sarscov
larg
kb
envelop
positivestrand
rna
viru
genom
compos
replicas
rep
spike
envelop
e
membran
nucleocapsid
n
gene
prophylact
therapeut
efficaci
sirna
test
absenc
effect
drug
vaccin
sarscov
infect
vitro
vivo
applic
prove
satisfactori
use
synthet
sirna
well
vectorbas
shrna
leader
sequenc
nonstructur
structur
gene
sarscov
tabl
anoth
recent
report
reveal
sirnamedi
deplet
host
cellular
clathrin
heavi
chain
gene
reduc
sarscov
infect
lock
nucleic
acid
lna
modifi
sirna
rnalik
high
affin
nucleotid
analogu
found
improv
perform
gene
silenc
via
enhanc
sirna
biostabl
specialti
improv
clearli
appar
sirna
transfect
vero
cell
prior
lethal
sarscov
attack
worth
mention
group
first
demonstr
remark
inhibit
replic
sarscov
infect
sirna
rep
gene
subsequ
design
sirna
could
target
rep
structur
gene
also
evalu
antivir
effect
dose
respons
durat
viral
kinet
sirna
foetal
rhesu
kidney
cell
two
sirna
evalu
safeti
antivir
efficaci
rhesu
macaqu
sar
model
fold
inhibit
viru
product
repres
potent
effect
caus
specif
sirna
combinatori
sirna
wwwwjgnetcom
sirna
reliev
sarslik
symptom
safe
prophylaxi
therapeut
treatment
find
greatli
encourag
clinic
test
sirna
antisar
therapi
influenza
viru
one
public
health
scourg
worldwid
three
influenza
epidem
occur
last
centuri
caus
ten
million
death
global
recent
outbreak
highli
pathogen
avian
influenza
asia
europ
greatli
increas
public
awar
acceler
develop
measur
prophylaxi
therapi
infect
influenza
virus
envelop
singlestrand
segment
rna
vir
use
belong
orthomyxovirida
famili
classifi
fold
inhibit
viru
product
refer
result
obtain
potent
sirnashrna
sirna
prepar
chemic
synthesi
unless
indic
otherwis
c
core
antigen
surfac
antigen
p
polymeras
x
x
protein
dr
direct
repeat
element
pfv
prototyp
foami
viru
aav
adenoassoci
viru
mous
human
human
express
plasmidnak
sirna
coinject
phbv
construct
express
plasmid
simultan
subsequ
inject
phbvpsag
construct
balbc
mice
inf
luenza
vir
us
type
b
c
base
nucleoprotein
matrix
protein
influenza
viru
iav
preval
respiratori
pathogen
worldwid
sinc
rna
viru
iav
abil
rapid
genet
chang
antigen
drift
antigen
shift
involv
accumul
minor
mutat
within
viral
genom
reassort
rna
segment
differ
virus
result
emerg
new
viral
strain
ge
et
al
tompkin
et
al
verifi
efficaci
sirna
specif
target
conserv
region
influenza
viru
genom
nucleocapsid
acid
polymeras
confirm
sirna
potent
inhibitor
influenza
viru
vitro
vivo
could
administ
prior
subsequ
lethal
iav
challeng
moreov
ge
develop
unconvent
deliveri
system
administ
small
volum
sirna
dna
vector
encod
shrna
complex
polyethyleneimin
pei
slow
intraven
infus
system
effect
reduc
viru
product
infect
mice
provid
help
suggest
futur
clinic
applic
sirna
sinc
rnai
found
antivir
activ
transgen
plant
much
evid
emerg
regard
pivot
role
antivir
therapeut
applic
numer
investig
report
success
inhibit
viral
replic
cultur
cell
murinenonhuman
primat
model
use
transient
transfect
synthet
sirna
stabl
express
shrna
har
full
potenti
rnai
therapeut
applic
pharmaceut
compani
activ
engag
clinic
trial
acuiti
pharmaceut
initi
clinic
trial
use
rnai
treatment
macular
degener
encourag
result
obtain
phase
studi
alnylam
pharmaceut
launch
phase
clinic
trial
us
inhal
formul
rnaibas
drug
combat
respiratori
syncyti
viru
rsv
infect
potenti
indic
rnai
use
includ
asthma
huntington
diseas
spinocerebellar
ataxia
hiv
hav
hbv
influenza
viru
infect
clinic
trial
consider
mani
condit
despit
rapid
progress
rnai
use
clinic
applic
still
pose
sever
challeng
includ
target
specif
biostabl
biosafeti
deliveri
efficaci
rnai
system
variou
diseas
recent
studi
indic
offtarget
effect
associ
use
sirna
order
improv
power
gene
silenc
avoid
undesir
advers
effect
induc
sirna
nonspecif
gene
silenc
immunoactiv
great
effort
made
improv
sirna
design
includ
sequenc
size
structur
howev
poor
pharmacokinet
properti
sirna
ad
anoth
hurdl
develop
rnaibas
therapi
multipl
chemic
modif
differ
posit
sirna
duplex
includ
sugar
backbon
base
oligonucleotid
found
prolong
sirna
halflif
serum
conjug
one
strand
sirna
lipid
peptid
shown
enhanc
nucleas
stabil
improv
cellular
uptak
systemat
sitespecif
deliveri
sirna
also
need
address
nonvir
vector
cation
lipid
polym
wide
use
vitro
vivo
sirna
deliveri
report
sirna
encapsul
stabl
nucleic
acid
lipid
particl
snalp
improv
potenc
lengthen
halflif
lower
effect
dose
reduc
dose
frequenc
obser
ved
studi
compar
unformul
sirna
rodent
challeng
replic
viru
nonhuman
primat
besid
song
et
al
design
protamineantibodi
fusion
protein
deliv
sirna
hivinfect
envelopetransfect
cell
studi
establish
system
celltyp
specif
antibodymedi
vivo
deliveri
system
sirna
via
cell
surfac
receptor
current
advanc
brought
sirna
close
era
clinic
trial
reallif
therapeut
applic
infect
human
subject
howev
rnaibas
clinic
trial
carri
toxic
sideeffect
rnai
harm
potenti
viral
vector
need
care
attent
shown
overexpress
shrna
doublestrand
viral
vector
result
sever
hepat
toxic
even
death
moreov
observ
overexpress
shrna
satur
mirna
pathway
studi
shown
simultan
deliveri
two
shrna
use
weaker
express
viral
vector
produc
obviou
liver
toxic
sideeffect
et
al
unpublish
therefor
essenti
use
safer
vector
respect
believ
induc
viral
vector
may
good
candid
futur
clinic
studi
scientist
differ
field
includ
geneticist
biochemist
pharmacologist
chemist
materi
scientist
support
use
rnai
clinic
applic
part
research
forc
team
cautiou
optimist
regard
use
rnai
human
diseas
